Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of daxdilimab in active proliferative lupus nephritis
MOH_2022-12-06_012208Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daxdilimab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Primary efficacy endpoint. Started Nov 2022; status: completed.
02
Drugs
daxdilimab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2022-12-06_012208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-06_012208.